Jan/Feb 2026 • PharmaTimes Magazine • 4-5


Contents


Features

2026 must be the year that pharma gets its data work back on track


Counterfeit drugs are spreading, forcing leaders to act with speed


The GLP-1 inflection point is a moment of reckoning for us all


Who, where and when? Redrawing your NHS stakeholder map for 2026


2026 life sciences trends – thriving in an AI-driven industry


Analysis

Five genomics trends set to reshape research and care in 2026


AI alone won’t solve pharma’s fragmented safety data problem


Why your next role depends on relationships you haven’t built yet


What’s topping pharma’s strategic agenda for 2026

How steady advances in radiology are making big waves


SmartPeople

12.
Patient-centric oncology trials
Data-driven, patient-first – using insights to transform cancer care


18.
Connect more
Redefining the future of customer relationships in biopharma


22.
Speaking volumes
Training confident spokespeople – a guide for health sector communicators


32.
Sharp focus
Rise of digital healthcare – shaping a new type of patient experience


36.
Movin' on up
The folk that are finding new challenges, colleagues and coffee cups


0